Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type.
Academic Article
Overview
abstract
BACKGROUND: Response to abrocitinib treatment for moderate-to-severe atopic dermatitis (AD) has not been evaluated across racial/ethnic subpopulations. OBJECTIVE: To assess efficacy and safety of abrocitinib based on patient race, ethnicity, and Fitzpatrick skin type (FST). METHODS: Data were pooled post hoc from patients treated with abrocitinib 200 mg, 100 mg, or placebo in 3 monotherapy trials (NCT02780167, NCT03349060, NCT03575871). Race and ethnicity were self-reported; FST was determined by study investigators. Evaluations through week 12 were Investigator's Global Assessment of clear or almost-clear skin (IGA 0/1); ≥75% improvement in Eczema Area and Severity Index (EASI-75) or SCORing Atopic Dermatitis (SCORAD-75); ≥4-point improvement in Peak Pruritus Numerical Rating Scale score (PP-NRS4); least squares mean changes in Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure (POEM) scores; and treatment-emergent adverse events (TEAEs). RESULTS: The sample comprised 628 White, 204 Asian, and 83 Black patients; 37 were Hispanic/Latino; 624 had FST I-III and 320 had FST IV-VI. Treatment with either abrocitinib dose was associated with higher IGA 0/1, EASI-75, SCORAD-75, and PP-NRS4 response rates or greater score changes from baseline in DLQI and POEM versus placebo regardless of race, ethnicity, or FST. Dose response was most prominent in White patients. In Black patients, the effects of the 2 doses were similar. TEAEs were more common in White and Black than in Asian patients. CONCLUSION: Abrocitinib was more efficacious than placebo across the racial/ethnic groups and ranges of phototypes analyzed. Studies with increased representation of populations of color are warranted to elucidate potential variations in response across diverse populations.
